LXEO: Lexeo Therapeutics, Inc. Stock

by  •  • Comments Off on LXEO: Lexeo Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 219.89
Enterprise Value ($M) 62.87
Book Value ($M) 139.33
Book Value / Share 4.21
Price / Book 1.58
NCAV ($M) 124.92
NCAV / Share 3.78
Price / NCAV 1.76

Profitability (mra)
Return on Invested Capital (ROIC) -0.58
Return on Assets (ROA) -1.58
Return on Equity (ROE) -3.90

Liquidity (mrq)
Quick Ratio 5.95
Current Ratio 5.95

Balance Sheet (mrq) ($M)
Current Assets 159.46
Assets 173.87
Liabilities 34.54
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
5 days ago 13G/A Lundbeckfond Invest A/S 2.90 -48.66
5 days ago 13G/A Eventide Asset Management, Llc 5.61 -15.34
5 days ago 13G/A Janus Henderson Group Plc 11.40 10.90
5 days ago 13G/A Longitude Capital Partners IV, LLC 8.40 7.72
7 days ago 13G Adage Capital Management, L.P. 7.86
02-14 13G D1 Capital Partners L.P. 9.40
02-14 13G Omega Fund VI, L.P. 8.10
02-14 13G/A Citadel Advisors Llc 7.80
12-15 13G/A Novo Holdings A/S 4.90 1.06

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURS
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PUR
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-12-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-18 93,463 483,188 19.34
2024-11-15 137,200 754,019 18.20
2024-11-14 125,635 1,004,669 12.51
2024-11-13 958,900 5,695,640 16.84

(click for more detail)

Similar Companies
LNTH – Lantheus Holdings, Inc. LRMR – Larimar Therapeutics, Inc.
LUMO – Lumos Pharma, Inc. MDWD – MediWound Ltd.
MIRM – Mirum Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io